Payne Stacey L, Fogelgren Ben, Hess Angela R, Seftor Elisabeth A, Wiley Elizabeth L, Fong Sheri F T, Csiszar Katalin, Hendrix Mary J C, Kirschmann Dawn A
Children's Memorial Research Center, Cancer Biology and Epigenomics Program, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine at Northwestern University, Chicago, IL 60614, USA.
Cancer Res. 2005 Dec 15;65(24):11429-36. doi: 10.1158/0008-5472.CAN-05-1274.
We have previously shown that lysyl oxidase (LOX) mRNA is up-regulated in invasive breast cancer cells and that catalytically active LOX facilitates in vitro cell invasion. Here we validate our in vitro studies by showing that LOX expression is up-regulated in distant metastatic breast cancer tissues compared with primary cancer tissues. To elucidate the mechanism by which LOX facilitates cell invasion, we show that catalytically active LOX regulates in vitro motility/migration and cell-matrix adhesion formation. Treatment of the invasive breast cancer cell lines, Hs578T and MDA-MB-231, with beta-aminopropionitrile (betaAPN), an irreversible inhibitor of LOX catalytic activity, leads to a significant decrease in cell motility/migration and adhesion formation. Conversely, poorly invasive MCF-7 cells expressing LOX (MCF-7/LOX32-His) showed an increase in migration and adhesion that was reversible with the addition of betaAPN. Moreover, a decrease in activated focal adhesion kinase (FAK) and Src kinase, key proteins involved in adhesion complex turnover, was observed when invasive breast cancer cells were treated with betaAPN. Additionally, FAK and Src activation was increased in MCF-7/LOX32-His cells, which was reversible on betaAPN treatment. Hydrogen peroxide was produced as a by-product of LOX activity and the removal of hydrogen peroxide by catalase treatment in invasive breast cancer cells led to a dose-dependent loss in Src activation. These results suggest that LOX facilitates migration and cell-matrix adhesion formation in invasive breast cancer cells through a hydrogen peroxide-mediated mechanism involving the FAK/Src signaling pathway. These data show the need to target LOX for treatment of aggressive breast cancer.
我们之前已经表明,赖氨酰氧化酶(LOX)mRNA在侵袭性乳腺癌细胞中上调,并且具有催化活性的LOX促进体外细胞侵袭。在此,我们通过显示与原发性癌组织相比,远处转移性乳腺癌组织中LOX表达上调来验证我们的体外研究。为了阐明LOX促进细胞侵袭的机制,我们表明具有催化活性的LOX调节体外运动性/迁移和细胞-基质粘附形成。用β-氨基丙腈(βAPN)(一种LOX催化活性的不可逆抑制剂)处理侵袭性乳腺癌细胞系Hs578T和MDA-MB-231,导致细胞运动性/迁移和粘附形成显著降低。相反,表达LOX的低侵袭性MCF-7细胞(MCF-7/LOX32-His)显示迁移和粘附增加,添加βAPN后这种增加是可逆的。此外,当用βAPN处理侵袭性乳腺癌细胞时,观察到参与粘附复合物周转的关键蛋白——活化的粘着斑激酶(FAK)和Src激酶减少。此外,MCF-7/LOX32-His细胞中FAK和Src的活化增加,βAPN处理后这种增加是可逆的。过氧化氢是LOX活性的副产物,在侵袭性乳腺癌细胞中用过氧化氢酶处理去除过氧化氢导致Src活化呈剂量依赖性丧失。这些结果表明,LOX通过涉及FAK/Src信号通路的过氧化氢介导机制促进侵袭性乳腺癌细胞的迁移和细胞-基质粘附形成。这些数据表明需要靶向LOX来治疗侵袭性乳腺癌。